Scholars@Duke
Angeles Alvarez Secord

Angeles Alvarez Secord

Professor of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
secor002@mc.duke.edu
Box 3079 Med Ctr, Durham, NC 27710
25172 Morris Bldg, Durham, NC 27710

Selected Publications

Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.

Journal Article Gynecol Oncol · January 23, 2025 PURPOSE: Determine if molecular classification using mismatch repair (MMR) and p53 protein expression predicts recurrence-free survival (RFS) and overall survival (OS) in endometrial cancer (EC) patients treated with chemotherapy and radiation (CRT) versus ... Full text Link to item Cite

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.

Journal Article Ann Oncol · November 29, 2024 BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRα)-targeting antibody-drug conjugate with United States Food and Drug Administration approval for FRα-positive platinum-resistant ovarian cancer. PICCOLO is a p ... Full text Link to item Cite

Real world challenges and disparities in the systemic treatment of ovarian cancer.

Journal Article Gynecol Oncol · June 2024 Ovarian cancer (OC) is a global health problem, and the mortality-to-incidence ratio is expected to increase, especially in low- and middle-income countries. These regions face disparities in access to OC care, including lack of awareness, limited access t ... Full text Link to item Cite

Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets.

Journal Article Gynecol Oncol · May 2024 OBJECTIVE: The treatment for high risk or recurrent gestational trophoblastic neoplasia (GTN) is a highly toxic multi-agent chemotherapy. For patients with progressive or recurrent GTN, checkpoint inhibitors have demonstrated anti-tumor activity; however, ... Full text Link to item Cite

Role of endometrial sampling to differentiate between advanced endometrial versus ovarian malignancy: retrospective cohort study.

Journal Article Int J Gynecol Cancer · April 1, 2024 OBJECTIVE: Distinguishing between advanced stage endometrial and ovarian cancer at diagnosis can be challenging, especially when patients do not present with abnormal uterine bleeding. Given emerging systemic therapies specific for ovarian versus endometri ... Full text Link to item Cite

High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.

Journal Article Gynecol Oncol · April 2024 OBJECTIVE: Uterine serous carcinoma is a highly aggressive non-endometrioid subtype of endometrial cancer with poor survival rates overall, creating a strong need for new therapeutic strategies to improve outcomes. High-dose ascorbate (vitamin C) has been ... Full text Link to item Cite

Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.

Journal Article Gynecol Oncol · April 2024 OBJECTIVE: Investigate racial disparities in outcomes and molecular features in Black and White patients with endometrioid endometrial carcinoma (EEC). METHODS: Black and White patients diagnosed with EEC who underwent hysterectomy ± adjuvant treatment in ... Full text Link to item Cite

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Journal Article J Clin Oncol · January 10, 2024 PURPOSE: To evaluate the addition of ofranergene obadenovec (ofra-vec, VB-111), a novel gene-based anticancer targeted therapy, to once a week paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC). METHODS: This placebo-controlled, ... Full text Link to item Cite

Abstract B028: Preclinical effects of Tumor Treating Fields (TTFields) applied with cisplatin for treatment of cervical cancer

Conference Cancer Research · January 9, 2024 AbstractIntroduction: Though largely preventable, cervical cancer remains a significant health issue. Treatment of early-stage disease usually involves surgery; while systemic therapy is often required for a ... Full text Cite

Management of malignant bowel obstruction - Authors' reply.

Journal Article Lancet Gastroenterol Hepatol · January 2024 Full text Link to item Cite

Management of malignant bowel obstruction Reply

Journal Article LANCET GASTROENTEROLOGY & HEPATOLOGY · 2024 Full text Cite

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma.

Journal Article Ann Med · December 2023 PURPOSE: Uterine serous carcinoma (USC) exhibits worse survival rates compared to the endometrioid subtype, and there is currently no effective treatment options for recurrence of this disease after platinum-based chemotherapy. Activation of PIK3CA/AKT/mTO ... Full text Link to item Cite

High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.

Journal Article Gynecol Oncol · December 2023 OBJECTIVE: We sought to evaluate the association between diet and angiogenic biomarkers in KpB mice, and the association between these markers, body mass index (BMI), and overall survival (OS) in high-grade serous cancers (HGSC). METHODS: Tumors previously ... Full text Link to item Cite

Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series.

Journal Article Gynecol Oncol Rep · December 2023 Cyclin-dependent kinase inhibitors are approved in combination with hormonal therapy for treatment of hormone receptor expressing breast cancers. Activity in hormone receptor expressing gynecologic cancers has been postulated. Granulosa cell tumor of the o ... Full text Link to item Cite

TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.

Journal Article Gynecol Oncol · November 2023 OBJECTIVE: This multi-center cohort study assessed associations between race, TP53 mutations, p53 expression, and histology to investigate racial survival disparities in endometrial cancer (EC). METHODS: Black and White patients with advanced or recurrent ... Full text Link to item Cite

Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.

Journal Article Gynecol Oncol · October 2023 OBJECTIVES: Clear cell carcinoma is a high-risk subtype of endometrial cancer. Some patients have a mixture of clear cell carcinoma with other histologic types (endometrioid or serous) or cannot be neatly assigned to one of these types. Protocol GOG-8032 w ... Full text Link to item Cite

Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial.

Journal Article Lancet Gastroenterol Hepatol · October 2023 BACKGROUND: Malignant small bowel obstruction has a poor prognosis and is associated with multiple related symptoms. The optimal treatment approach is often unclear. We aimed to compare surgical versus non-surgical management with the aim to determine the ... Full text Link to item Cite

Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo.

Journal Article Int J Oncol · September 2023 Endometrial cancer is the most common gynecologic cancer and one of the only cancers for which incidence and mortality is steadily increasing. Although curable with surgery in the early stages, endometrial cancer presents a significant clinical challenge i ... Full text Link to item Cite

Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.

Journal Article Gynecol Oncol · July 2023 OBJECTIVE: To determine the effects of using National Comprehensive Cancer Network (NCCN) guidelines to estimate renal function on carboplatin dosing and explore adverse effects associated with a more accurate estimation of lower creatinine clearance (CrCl ... Full text Link to item Cite

Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score.

Journal Article Gynecol Oncol · July 2023 OBJECTIVE: Malignancy-associated bowel obstruction (MBO) is a potential sequela of advanced gynecologic cancers, adversely impacting both quality of life and prognosis. The Henry score (HS) was developed in a gastrointestinal cancer-predominant population ... Full text Link to item Cite

The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.

Journal Article Gynecol Oncol · June 2023 OBJECTIVE: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance, toxicities, progression free survival (PFS), time from sur ... Full text Link to item Cite

Abstract 2666: Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin or paclitaxel for treatment of cervical cancer

Conference Cancer Research · April 4, 2023 AbstractIntroduction: Cervical cancer is a serious health problem despite the fact it is highly preventable. Early-stage cervical cancer treatment often involves surgery; however advanced, recurrent, or meta ... Full text Cite

Molecular testing for endometrial cancer: An SGO clinical practice statement.

Journal Article Gynecol Oncol · January 2023 The Cancer Genome Atlas publication first described the genomic landscape of endometrial cancer and characterized these cancers into four molecular subtypes with different prognoses. The Proactive Molecular Classifier for Endometrial Cancer was developed t ... Full text Link to item Cite

A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.

Journal Article Gynecol Oncol · December 2022 OBJECTIVE: The primary objective of the study was to estimate the 12-month progression-free survival (PFS) for carboplatin/paclitaxel + temsirolimus in women with newly diagnosed clear cell ovarian cancer (CCOC), compared to historical controls in this pat ... Full text Link to item Cite

Transfusion Requirements with Hybrid Management of Placenta Accreta Spectrum Incorporating Targeted Embolization and a Selective Use of Delayed Hysterectomy.

Journal Article Am J Perinatol · October 2022 OBJECTIVE: This study compares the number of units of red blood cells (RBCs) transfused in patients with placenta accreta spectrum (PAS) treated with or without a multidisciplinary algorithm that includes placental uterine arterial embolization (P-UAE) and ... Full text Link to item Cite

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Journal Article J Clin Oncol · October 1, 2022 PURPOSE: The status of p53 in a tumor can be inferred by next-generation sequencing (NGS) or by immunohistochemistry (IHC). We examined the association between p53 IHC and sequence and whether p53 IHC alone, or integrated with TP53 NGS, predicts the outcom ... Full text Link to item Cite

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.

Journal Article Gynecol Oncol · September 2022 OBJECTIVE: Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free surviv ... Full text Link to item Cite

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.

Journal Article J Clin Oncol · July 1, 2022 PURPOSE: Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed the activity of two all-oral nonplatinum alternatives, olaparib or olaparib/cediranib, v ... Full text Link to item Cite

Novel Therapies in Gynecologic Cancer.

Journal Article Am Soc Clin Oncol Educ Book · April 2022 During the past decade, considerable strides have been made in the understanding and treatment of gynecologic cancers. The advent of PARP inhibitors, antiangiogenic therapies, immunotherapy combinations, and targeted agents have altered the standard of car ... Full text Link to item Cite

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.

Journal Article J Clin Oncol · March 20, 2022 PURPOSE: This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS). PATIENTS AND METHODS: Adults with chemotherapy-n ... Full text Link to item Cite

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.

Journal Article Lancet · February 5, 2022 BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choi ... Full text Link to item Cite

Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancer.

Journal Article Am J Cancer Res · 2022 Ipatasertib (IPAT) is an orally administered, selective protein kinase B (AKT) inhibitor with promising data in solid tumors in both pre-clinical studies and clinical trials. Given that the PI3K/AKT/mTOR pathway is frequently dysregulated in uterine serous ... Link to item Cite

Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer.

Journal Article Int J Gynecol Cancer · December 2021 OBJECTIVE: The role and type of adjuvant therapy for patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIA grade 1 endometrioid endometrial adenocarcinoma are controversial. This retrospective cohort study aimed to determine ... Full text Link to item Cite

Obesity and altered angiogenic-related gene expression in endometrial cancer.

Journal Article Gynecol Oncol · November 2021 OBJECTIVES: Evaluate association between obesity and angiogenic-related gene expression in endometrial cancer (EC). Evaluate interaction between diet and metformin on angiogenic-related gene expression. METHODS: We evaluated the association between 168 hum ... Full text Link to item Cite

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.

Journal Article Gynecol Oncol · October 2021 OBJECTIVES: The clinical utility of maintenance therapy (MT) for patients with platinum-sensitive recurrent ovarian cancer has been validated in several clinical trials. We assessed "real-world" treatment patterns using an electronic health record (EHR) da ... Full text Link to item Cite

The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.

Journal Article Gynecol Oncol · August 2021 OBJECTIVE: To assess preferences of women with ovarian cancer regarding features of available anti-cancer regimens for platinum-resistant, biomarker-positive disease, with an emphasis on oral PARP inhibitor and standard intravenous (IV) chemotherapy regime ... Full text Link to item Cite

Placental uterine artery embolization followed by delayed hysterectomy for placenta percreta: A case series.

Journal Article Gynecol Oncol Rep · August 2021 We describe outcomes of patients with suspected placenta percreta treated with placental uterine artery embolization (P-UAE) followed by delayed hysterectomy. This is a prospective case series of subjects from 2005 to 2018 with suspected placenta percreta ... Full text Link to item Cite

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.

Journal Article Gynecol Oncol · August 2021 Inhibitors of poly(ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to establish whether combination therapy can augment the response seen with PARP inhi ... Full text Link to item Cite

Molecular Classification to Prognosticate Response in Medically Managed Endometrial Cancers and Endometrial Intraepithelial Neoplasia.

Journal Article Cancers (Basel) · June 7, 2021 BACKGROUND: The aim of this study was to evaluate whether molecular classification prognosticates treatment response in women with endometrial cancers and endometrial intraepithelial neoplasia (EIN) treated with levonorgestrel intrauterine system (LNG-IUS) ... Full text Link to item Cite

LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.

Conference Journal of Clinical Oncology · May 20, 2021 5538 Background: The phase (Ph) 1b part of LIO-1 (NCT04042116; ENGOT-GYN3/AGO/LIO) assessed the oral antiangiogenic, multikinase inhibitor lucitanib + immune checkpoint inhibitor nivolumab, confirming the recommended Ph2 dose (RP ... Full text Cite

Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Conference Journal of Clinical Oncology · May 20, 2021 TPS5599 Background: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism of action that includes a broad antiangiogenic effect and induction of a tumor directed immune response. A phase II ... Full text Cite

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).

Conference Journal of Clinical Oncology · May 20, 2021 TPS5605 Background: The AXL receptor and its activating ligand, GAS6, are important drivers of metastasis and therapeutic resistance in human cancers. This signaling axis represents an attractive target for therapeutic interventi ... Full text Cite

FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study.

Conference Journal of Clinical Oncology · May 20, 2021 TPS5606 Background: Oregovomab binds tumor-associated CA125 rendering the target antigen CA125 more immunogenic or “neoantigen-like” through altered and enhanced antigen processing and presentation to specific T cells. This pheno ... Full text Cite

Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.

Journal Article Gynecol Oncol · May 2021 OBJECTIVE: Report the results from a preplanned interim analysis of a phase III, double blind, randomized controlled study of ofranergene obadenovec (VB-111), a targeted anti-cancer gene therapy, in combination with paclitaxel in patients with platinum res ... Full text Link to item Cite

Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).

Journal Article Gynecol Oncol · May 2021 PURPOSE: Increasing measures of adiposity have been correlated with poor oncologic outcomes and a lack of response to anti-angiogenic therapies. Limited data exists on the impact of subcutaneous fat density (SFD) and visceral fat density (VFD) on oncologic ... Full text Link to item Cite

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

Journal Article Gynecol Oncol · April 2021 BACKGROUND: Successfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivity. N ... Full text Link to item Cite

The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.

Journal Article Gynecol Oncol · March 2021 OBJECTIVE: While most cases of endometrial cancer can readily be classified as pure endometrioid, pure serous, or another type, others show an apparent mixture of serous and endometrioid components, or indeterminate serous versus endometrioid features. Sin ... Full text Link to item Cite

H2O2-Driven Anticancer Activity of Mn Porphyrins and the Underlying Molecular Pathways.

Journal Article Oxid Med Cell Longev · 2021 Mn(III) ortho-N-alkyl- and N-alkoxyalkyl porphyrins (MnPs) were initially developed as superoxide dismutase (SOD) mimics. These compounds were later shown to react with numerous reactive species (such as ONOO-, H2O2, H2S, CO3 •-, ascorbate, and GSH). Moreo ... Full text Open Access Link to item Cite

A Pilot Study of Home-Based Exercise and Personalized Nutrition Counseling Intervention in Endometrial Cancer Survivors.

Journal Article Front Oncol · 2021 INTRODUCTION: To assess the feasibility of a home-based aerobic exercise and nutrition counseling intervention and effect on cardiorespiratory fitness, cardiovascular disease risk profile, and immune response in obese endometrial cancer survivors. METHODS: ... Full text Link to item Cite

Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population.

Journal Article Obstet Gynecol · December 2020 INTRODUCTION: To gain a better understanding of gynecologic oncology patient adherence to oral anticancer agents through both a cross-sectional survey of adherence and qualitative interviews with patients and clinicians regarding their experience with thes ... Full text Link to item Cite

Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.

Journal Article Int J Gynecol Cancer · November 2020 BACKGROUND: Adjuvant therapy in early-stage endometrial cancer has not shown a clear overall survival benefit, and hence, patient selection remains crucial. OBJECTIVE: To determine whether women with high-intermediate risk, early-stage endometrial cancer w ... Full text Link to item Cite

Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.

Journal Article Gynecol Oncol · November 2020 OBJECTIVES: Clinical trials evaluating universal PARP inhibitor (PARPi) frontline maintenance therapy for advanced stage ovarian cancer have reported progression-free survival (PFS) benefit. It is unclear whether PARPi maintenance therapy will universally ... Full text Link to item Cite

MnTnBuOE-2-PyP5+ Ascorbate in the Treatment of Ovarian Cancer

Conference Free Radical Biology and Medicine · November 2020 Full text Cite

Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.

Journal Article Int J Gynecol Cancer · October 2020 OBJECTIVE: Limited information exists regarding risk reduction strategies for women with moderate and low penetrance ovarian cancer susceptibility mutations. We sought to assess current risk reduction practice patterns for carriers of these mutations throu ... Full text Link to item Cite

Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.

Journal Article Clin Cancer Res · August 1, 2020 PURPOSE: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/pa ... Full text Link to item Cite

Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report.

Journal Article Gynecol Oncol Rep · August 2020 This case report describes a 46-year-old patient with rapidly progressive stage IIIA1 estrogen receptor positive low grade serous ovarian cancer (LGSC). She was optimally debulked with no residual disease and received three cycles of adjuvant liposomal dox ... Full text Link to item Cite

Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.

Journal Article Gynecol Oncol · July 2020 OBJECTIVES: The COVID-19 pandemic has consumed considerable resources and has impacted the delivery of cancer care. Patients with cancer may have factors which place them at high risk for COVID 19 morbidity or mortality. Highly immunosuppressive chemothera ... Full text Link to item Cite

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Journal Article Gynecologic oncology · June 2020 ObjectiveAngiogenesis inhibition is a valuable strategy for ovarian cancer (EOC). Pazopanib (paz) is a potent small molecular inhibitor of VEGF-1, -2, -3, PDGFR, c-kit, and has activity as a single agent in ovarian cancer. We designed a trial to a ... Full text Cite

Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer.

Journal Article Int J Gynecol Cancer · April 2020 OBJECTIVES: Neoadjuvant chemotherapy may be considered for women with epithelial ovarian cancer who have poor performance status or a disease burden not amenable to primary cytoreductive surgery. Overlap exists between indications for neoadjuvant chemother ... Full text Link to item Cite

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.

Journal Article Clin Cancer Res · March 15, 2020 PURPOSE: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrate ... Full text Link to item Cite

Differential expression of immune related genes in high-grade ovarian serous carcinoma.

Journal Article Gynecol Oncol · March 2020 OBJECTIVE: To identify novel immunologic targets and biomarkers associated with overall survival (OS) in high-grade serous ovarian cancer (HGSC). METHODS: In this retrospective study, microarray data from 51 HGSC specimens were analyzed (Affymetrix HG-U133 ... Full text Link to item Cite

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Journal Article Gynecol Oncol · March 2020 OBJECTIVES: Intraperitoneal (IP) chemotherapy following neoadjuvant chemotherapy (NACT) and interval tumor reductive surgery (TRS) for advanced ovarian cancer is feasible, however, the impact on disease outcomes remains unclear. We compare outcomes of pati ... Full text Link to item Cite

Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?

Journal Article Gynecol Oncol · March 2020 OBJECTIVES: Lymphovascular space invasion (LVSI) is an independent risk factor for recurrence and poor survival in early-stage endometrioid endometrial cancer (EEC), but optimal adjuvant treatment is unknown. We aimed to compare the survival of women with ... Full text Link to item Cite

Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.

Journal Article Gynecol Oncol · March 2020 OBJECTIVE: To measure preferences of women with ovarian cancer regarding risks, side effects, costs and benefits afforded by maintenance therapy (MT) with a poly ADP ribose polymerase (PARP) inhibitor. METHODS: A discrete-choice experiment elicited prefere ... Full text Link to item Cite

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Journal Article Clin Cancer Res · March 1, 2020 PURPOSE: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a secon ... Full text Link to item Cite

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

Journal Article Obstetrical and Gynecological Survey · March 1, 2020 Full text Cite

European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.

Journal Article Gynecol Oncol · February 2020 Multiple practice changing studies were presented at the 2019 ESMO Congress in Barcelona, Spain. The ovarian cancer studies presented at the Presidential session will likely refine and redefine the initial treatment of ovarian cancer. Other compelling tria ... Full text Link to item Cite

Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316).

Journal Article Am J Hosp Palliat Care · January 2020 BACKGROUND: Prospective, randomized trials are needed to determine optimal treatment approaches for palliative care problems such as malignant bowel obstruction (MBO). Randomization poses unique issues for such studies, especially with divergent treatment ... Full text Link to item Cite

Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.

Journal Article Cancer · December 15, 2019 BACKGROUND: Randomized trials have reported conflicting findings on survival for advanced-stage ovarian cancer treated with primary debulking surgery (PDS) versus neoadjuvant chemotherapy with interval debulking; surgical complications and mortality are hi ... Full text Link to item Cite

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Journal Article N Engl J Med · November 14, 2019 BACKGROUND: Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation. METHODS: We rando ... Full text Link to item Cite

Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.

Journal Article Gynecol Oncol · July 2019 OBJECTIVE: Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially ... Full text Link to item Cite

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.

Journal Article Gynecol Oncol · June 2019 BACKGROUND: Bevacizumab provides benefit in epithelial ovarian cancer (EOC), yet resistance to bevacizumab often occurs. We determined if nintedanib, a tyrosine kinase inhibitor of VEGF, FGF, and PDGF receptors has antitumor activity in bevacizumab-resista ... Full text Link to item Cite

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Journal Article J Clin Oncol · June 1, 2019 PURPOSE: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS: Eligible patients were randomly assigned to six cycles of I ... Full text Link to item Cite

Patient preferences for maintenance PARP therapy in ovarian cancer treatment.

Conference Journal of Clinical Oncology · May 20, 2019 5558 Background: Maintenance therapy with PARP inhibitors has become prevalent in treating ovarian cancer. However, the preferences of women with ovarian cancer regarding the risks, side effects and benefits afforded by maintenan ... Full text Cite

Management of high, moderate, and low penetrance ovarian cancer susceptibility gene mutations: An assessment of current practice patterns.

Conference Journal of Clinical Oncology · May 20, 2019 1536 Background: Limited information exists regarding appropriate risk-reduction strategies for women with moderate and low penetrance ovarian cancer (OVCA) susceptibility mutations. We sought to assess current practice patterns ... Full text Cite

AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.

Conference Journal of Clinical Oncology · May 20, 2019 TPS5608 Background: Prognosis of advanced/recurrent endometrial cancer (EC) is poor with median survival of 12-15 months for patients with measurable disease. Treatment options are limited, with primary management being chemother ... Full text Cite

Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.

Conference Journal of Clinical Oncology · May 20, 2019 5557 Background: The Food and Drug Administration approved the use of bevacizumab for treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (OC) in combination with chemotherapy. This study e ... Full text Cite

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.

Conference Journal of Clinical Oncology · May 20, 2019 5500 Background: Gynecologic carcinosarcomas (CS) are rare yet aggressive epithelial malignancies for which optimal therapy is debated. PI was shown to be superior to I. PC demonstrated compelling phase 2 activity with improved s ... Full text Cite

Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma.

Journal Article World J Surg Oncol · May 10, 2019 OBJECTIVE: To investigate the predictive value of lymphovascular space invasion (LVSI) for nodal recurrence and overall survival (OS) in patients with stage I endometrioid endometrial cancer (EC) following surgical staging that included adequate lymph node ... Full text Link to item Cite

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.

Journal Article Gynecol Oncol · May 2019 OBJECTIVES: A recent randomized controlled trial demonstrated an overall survival benefit to the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to neoadjuvant chemotherapy (NACT) for stage III epithelial ovarian cancer (EOC). The objective o ... Full text Link to item Cite

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Journal Article Lancet Oncol · May 2019 BACKGROUND: Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5-9 months. In this study (QUAD ... Full text Link to item Cite

The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.

Journal Article Gynecol Oncol · April 2019 BACKGROUND: Granulosa cell tumors (GCT) variably express estrogen receptors (ER) and progesterone receptors (PR). The goal of this study is to evaluate the relationship between ER and PR expression patterns and clinical outcomes in women with GCT. METHODS: ... Full text Link to item Cite

Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Journal Article Cancer Chemother Pharmacol · April 2019 PURPOSE: Anticancer drugs may cause cardiovascular toxicities, including QT interval prolongation. Niraparib, a potent and selective once-daily oral poly (ADP-ribose) polymerase inhibitor, is approved as a maintenance therapy in platinum-sensitive recurren ... Full text Link to item Cite

U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.

Journal Article Obstet Gynecol · April 2019 OBJECTIVE: We sought to determine whether use of a poly (ADP-ribose) polymerase inhibitor is cost effective for maintenance treatment of platinum-sensitive recurrent ovarian cancer. METHODS: A decision analysis model compared four maintenance strategies: 1 ... Full text Link to item Cite

Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.

Journal Article Gynecol Oncol · March 2019 OBJECTIVES: FDA-approved treatments for platinum-sensitive recurrent ovarian cancer (PSROC) include bevacizumab and PARP inhibitors (PARPi); clinical decisions regarding therapy must be made prior to initiating chemotherapy. Using the American Society of C ... Full text Link to item Cite

Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.

Journal Article Gynecol Oncol · March 2019 OBJECTIVES: To evaluate surgical complexity scores (SCS) and minimally invasive surgery (MIS) at interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC) patients receiving neoadjuvant chemotherapy (NACT). METHODS: A multi-institutional ... Full text Link to item Cite

Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management.

Journal Article Obstet Gynecol Clin North Am · March 2019 Ovarian cancer treatment continues to evolve. Despite aggressive surgery and chemotherapy, most women will ultimately die from disease. Improvement in disease control are due to the incorporation of molecular targeted agents and the adoption of maintenance ... Full text Link to item Cite

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Journal Article Obstet Gynecol · February 2019 OBJECTIVE: To analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian-peritoneal-tubal carcinoma and to develop a nomogram to predict individual survival after recurrence. METHODS: We retrospectively analyzed ... Full text Link to item Cite

Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis.

Journal Article Gynecol Oncol · December 2018 OBJECTIVES: Sentinel lymph node biopsy (SLNB) may be considered in the setting of a pre-operative diagnosis of endometrial intraepithelial neoplasia (EIN) due to high rates of concurrent invasive cancer. The aim of this study is to compare the cost-effecti ... Full text Link to item Cite

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

Journal Article Gynecol Oncol · December 2018 OBJECTIVE: Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in pati ... Full text Link to item Cite

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.

Journal Article Gynecol Oncol · November 2018 PURPOSE: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathways, resulting in mTOR activation. We evaluated combining BV and everolimus (EV), an mTOR kinase inhibitor, to circumvent BV-resistance in women with recurr ... Full text Link to item Cite

Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

Journal Article Cancer Treat Rev · September 2018 Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to th ... Full text Link to item Cite

GOG213

Conference INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER · September 1, 2018 Link to item Cite

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

Journal Article Gynecol Oncol · August 2018 OBJECTIVE: Paclitaxel and carboplatin (PC) is a standard initial therapy for advanced endometrial cancer. We evaluated the efficacy and tolerability of incorporating three novel agents into initial therapy. METHODS: In this randomized phase II trial, patie ... Full text Link to item Cite

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

Journal Article Gynecol Oncol · August 2018 OBJECTIVES: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. METHODS: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphol ... Full text Link to item Cite

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Journal Article J Clin Oncol · July 10, 2018 Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcino ... Full text Link to item Cite

A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.

Journal Article Clin Cancer Res · May 15, 2018 Purpose: Epigenetic changes are implicated in acquired resistance to platinum. Guadecitabine is a next-generation hypomethylating agent (HMA). Here, we report the clinical results, along with pharmacokinetic (PK) and pharmacodynamic analyses of the phase I ... Full text Link to item Cite

Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer.

Journal Article Int J Gynecol Pathol · May 2018 To determine whether the processing of additional adipose tissue collected during lymph node (LN) dissection results in the identification of additional LNs during endometrial cancer (EC) staging and to determine if the division of LNs into nodal basin-spe ... Full text Link to item Cite

The Immune Landscape of Cancer.

Journal Article Immunity · April 17, 2018 We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified six immune subtypes-wound healing, IFN-γ dominant, inflammatory, lymphocyt ... Full text Link to item Cite

Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.

Journal Article Cancer Cell · April 9, 2018 We analyzed 921 adenocarcinomas of the esophagus, stomach, colon, and rectum to examine shared and distinguishing molecular characteristics of gastrointestinal tract adenocarcinomas (GIACs). Hypermutated tumors were distinct regardless of cancer type and c ... Full text Link to item Cite

lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.

Journal Article Cancer Cell · April 9, 2018 We characterized the epigenetic landscape of genes encoding long noncoding RNAs (lncRNAs) across 6,475 tumors and 455 cancer cell lines. In stark contrast to the CpG island hypermethylation phenotype in cancer, we observed a recurrent hypomethylation of 1, ... Full text Link to item Cite

Genomic and Functional Approaches to Understanding Cancer Aneuploidy.

Journal Article Cancer Cell · April 9, 2018 Aneuploidy, whole chromosome or chromosome arm imbalance, is a near-universal characteristic of human cancers. In 10,522 cancer genomes from The Cancer Genome Atlas, aneuploidy was correlated with TP53 mutation, somatic mutation rate, and expression of pro ... Full text Link to item Cite

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.

Journal Article Cancer Cell · April 9, 2018 We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of four gynecological types plus breast. Our aims were to identify shared and unique molecular features, clinically significant subtypes, and potential therapeutic targets. We f ... Full text Link to item Cite

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.

Journal Article Cell · April 5, 2018 The Cancer Genome Atlas (TCGA) has catalyzed systematic characterization of diverse genomic alterations underlying human cancers. At this historic junction marking the completion of genomic characterization of over 11,000 tumors from 33 cancer types, we pr ... Full text Link to item Cite

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Journal Article Cell · April 5, 2018 We conducted comprehensive integrative molecular analyses of the complete set of tumors in The Cancer Genome Atlas (TCGA), consisting of approximately 10,000 specimens and representing 33 types of cancer. We performed molecular clustering using data on chr ... Full text Link to item Cite

Pathogenic Germline Variants in 10,389 Adult Cancers.

Journal Article Cell · April 5, 2018 We conducted the largest investigation of predisposition variants in cancer to date, discovering 853 pathogenic or likely pathogenic variants in 8% of 10,389 cases from 33 cancer types. Twenty-one genes showed single or cross-cancer associations, including ... Full text Link to item Cite

A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.

Journal Article Cell · April 5, 2018 The role of enhancers, a key class of non-coding regulatory DNA elements, in cancer development has increasingly been appreciated. Here, we present the detection and characterization of a large number of expressed enhancers in a genome-wide analysis of 892 ... Full text Link to item Cite

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Journal Article Cell · April 5, 2018 Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-occurrence of alterations in these pathways differ between individual tumors and tu ... Full text Link to item Cite

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.

Journal Article Cell · April 5, 2018 Cancer progression involves the gradual loss of a differentiated phenotype and acquisition of progenitor and stem-cell-like features. Here, we provide novel stemness indices for assessing the degree of oncogenic dedifferentiation. We used an innovative one ... Full text Link to item Cite

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

Journal Article Cell · April 5, 2018 For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features represe ... Full text Link to item Cite

Comprehensive Characterization of Cancer Driver Genes and Mutations.

Journal Article Cell · April 5, 2018 Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on large datasets are few. We report a PanCancer and PanSoftware analy ... Full text Link to item Cite

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Journal Article Cell Rep · April 3, 2018 Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, includ ... Full text Link to item Cite

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.

Journal Article Cell Rep · April 3, 2018 Long noncoding RNAs (lncRNAs) are commonly dysregulated in tumors, but only a handful are known to play pathophysiological roles in cancer. We inferred lncRNAs that dysregulate cancer pathways, oncogenes, and tumor suppressors (cancer genes) by modeling th ... Full text Link to item Cite

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.

Journal Article Cell Rep · April 3, 2018 Gene fusions represent an important class of somatic alterations in cancer. We systematically investigated fusions in 9,624 tumors across 33 cancer types using multiple fusion calling tools. We identified a total of 25,664 fusions, with a 63% validation ra ... Full text Link to item Cite

Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.

Journal Article Cell Rep · April 3, 2018 Beyond sample curation and basic pathologic characterization, the digitized H&E-stained images of TCGA samples remain underutilized. To highlight this resource, we present mappings of tumor-infiltrating lymphocytes (TILs) based on H&E images from 13 TCGA t ... Full text Link to item Cite

Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.

Journal Article Cell Rep · April 3, 2018 Metabolic reprogramming provides critical information for clinical oncology. Using molecular data of 9,125 patient samples from The Cancer Genome Atlas, we identified tumor subtypes in 33 cancer types based on mRNA expression patterns of seven major metabo ... Full text Link to item Cite

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Journal Article Cell Rep · April 3, 2018 This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and other recu ... Full text Link to item Cite

Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.

Journal Article Cell Rep · April 3, 2018 Protein ubiquitination is a dynamic and reversible process of adding single ubiquitin molecules or various ubiquitin chains to target proteins. Here, using multidimensional omic data of 9,125 tumor samples across 33 cancer types from The Cancer Genome Atla ... Full text Link to item Cite

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.

Journal Article Cell Rep · April 3, 2018 Precision oncology uses genomic evidence to match patients with treatment but often fails to identify all patients who may respond. The transcriptome of these "hidden responders" may reveal responsive molecular states. We describe and evaluate a machine-le ... Full text Link to item Cite

Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.

Journal Article Cell Rep · April 3, 2018 Hotspot mutations in splicing factor genes have been recently reported at high frequency in hematological malignancies, suggesting the importance of RNA splicing in cancer. We analyzed whole-exome sequencing data across 33 tumor types in The Cancer Genome ... Full text Link to item Cite

Systematic Analysis of Splice-Site-Creating Mutations in Cancer.

Journal Article Cell Rep · April 3, 2018 For the past decade, cancer genomic studies have focused on mutations leading to splice-site disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic tool, MiSplice, for the large-scale discovery of splice-site-creat ... Full text Link to item Cite

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.

Journal Article Cell Rep · April 3, 2018 DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We systematically analyzed somatic alterations to provide a comprehensive view of DDR deficiency across 33 cancer types. Mutations with accompanying loss of heter ... Full text Link to item Cite

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

Journal Article Cell Syst · March 28, 2018 Although the MYC oncogene has been implicated in cancer, a systematic assessment of alterations of MYC, related transcription factors, and co-regulatory proteins, forming the proximal MYC network (PMN), across human cancers is lacking. Using computational ... Full text Link to item Cite

Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.

Journal Article Cell Syst · March 28, 2018 The Cancer Genome Atlas (TCGA) cancer genomics dataset includes over 10,000 tumor-normal exome pairs across 33 different cancer types, in total >400 TB of raw data files requiring analysis. Here we describe the Multi-Center Mutation Calling in Multiple Can ... Full text Link to item Cite

Urinary diversion in the genitourinary cancer survivor.

Journal Article Gynecol Oncol · February 2018 Urinary diversion has been in the scope of practice of Gynecologic Oncologists since the inception of the sub-specialty. However, many fewer urinary diversions are performed currently than in the past due to improved prevention of cervical cancer. The inte ... Full text Link to item Cite

Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.

Journal Article Int J Gynecol Cancer · February 2018 OBJECTIVE: Predictive models are increasingly being used in clinical practice. The aim of the study was to develop a predictive model to identify patients with platinum-resistant ovarian cancer with a prognosis of less than 6 to 12 months who may benefit f ... Full text Link to item Cite

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Journal Article JAMA Oncol · February 1, 2018 IMPORTANCE: Ovarian cancer is the leading cause of gynecologic cancer deaths in the United States. Pazopanib is an oral, multitarget kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptors α an ... Full text Link to item Cite

Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy.

Journal Article Gynecol Oncol Res Pract · 2018 BACKGROUND: Widespread concerns have been raised regarding the safety of power morcellation of uterine specimens because of the potential to disseminate occult malignancy. We sought to assess the safety and feasibility of contained manual uterine morcellat ... Full text Link to item Cite

ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.

Journal Article J Oncol Pract · December 2017 PURPOSE: The ASCO value framework allows physicians and patients to compare the relative value of novel treatments. Our aim was to assess the value of three frontline ovarian cancer therapies by using this framework. METHODS: From phase III, randomized con ... Full text Link to item Cite

Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer.

Journal Article Gynecol Oncol · December 2017 OBJECTIVES: To evaluate the capability of a novel sentinel lymph node (SLN) mapping algorithm to reduce the need for pelvic lymphadenectomy (PLND) in patients with low-grade (G1-2) endometrial cancer (LGEC). METHODS: Patients with LGEC underwent evaluation ... Full text Link to item Cite

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Journal Article Gynecol Oncol · November 2017 PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 pro ... Full text Link to item Cite

Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.

Journal Article Gynecol Oncol · October 2017 OBJECTIVE: Evaluate association between baseline quality of life (QOL) and changes in QOL measured by FACT-O TOI with progression-free disease (PFS) and overall survival (OS) in advanced epithelial ovarian cancer (EOC). METHODS: Patients enrolled in GOG-02 ... Full text Link to item Cite

Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO’s net health benefits (NHB) inform our decisions?

Conference Journal of Clinical Oncology · May 20, 2017 5544 Background: The ASCO value framework allows assessment of novel cancer therapies based on NHB. We assessed novel biologic therapies in the management of PSROC. Methods: ASCO’s revised value framework NHBs were constructed fo ... Full text Cite

Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer.

Conference Journal of Clinical Oncology · May 20, 2017 5571 Background: Understanding the immune checkpoint marker repertoire can facilitate development of therapeutic strategies to improve efficacy of immune-based therapies. We used a novel high-dimensional flow cytometry panel to d ... Full text Cite

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Conference Journal of Clinical Oncology · May 20, 2017 5532 Background: Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer. Pazopanib (paz) is a potent angiogenic small molecular inhibitor of the tyrosine kinases VEGRF-1, -2, -3, PDGFR, c-kit and has shown ... Full text Cite

Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Journal Article Cancer · April 1, 2017 BACKGROUND: Synuclein-γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the l ... Full text Link to item Cite

Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.

Journal Article Gynecol Oncol · March 2017 OBJECTIVES: To evaluate progression-free survival (PFS) and overall survival (OS) outcomes in women diagnosed with uterine papillary serous carcinoma (UPSC) who have had (UPSCBR+) or have not had (UPSCBR-) an antecedent history of breast cancer and to corr ... Full text Link to item Cite

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

Journal Article Gynecol Oncol · March 2017 PURPOSE: A simple measure to predict chemotherapy tolerance in elderly patients would be useful. We prospectively tested the association of baseline Instrumental Activities of Daily Living (IADL) score with ability to complete 4 cycles of first line chemot ... Full text Link to item Cite

Angiogenesis

Chapter · February 22, 2017 Angiogenesis is a complex multifaceted process essential for cancer growth and progression. The underlying biology regulating angiogenesis is incredibly complicated, involving interaction between cancer cells and the tumor microenvironment. Angiogenic grow ... Full text Cite

Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.

Journal Article J Oncol Pract · February 2017 PURPOSE: The advent of multigene panels has increased genetic testing options for women with epithelial ovarian cancer (EOC). We designed a decision model to compare costs and probabilities of identifying a deleterious mutation or variant of uncertain sign ... Full text Link to item Cite

Disparities in the surgical staging of high-grade endometrial cancer in the United States.

Journal Article Gynecol Oncol Res Pract · 2017 BACKGROUND: The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer. Our goal was to examine surgical sta ... Full text Open Access Link to item Cite

Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes.

Journal Article Gynecol Oncol Res Pract · 2017 BACKGROUND: Due to the significant morbidity and mortality associated with placenta percreta, alternative management options are needed. Beginning in 2005, our institution implemented a multidisciplinary strategy to patients with suspected placenta percret ... Full text Open Access Link to item Cite

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.

Journal Article Gynecol Oncol · December 2016 OBJECTIVES: To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical ... Full text Link to item Cite

Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis.

Journal Article Obstet Gynecol · October 2016 OBJECTIVE: To estimate the cost-effectiveness of the levonorgestrel intrauterine device (IUD) as an endometrial cancer prevention strategy in obese women. METHODS: A modified Markov model was used to compare IUD placement at age 50 with usual care among wo ... Full text Link to item Cite

Performance of sentinel lymph node biopsy in high-risk endometrial cancer.

Journal Article Gynecol Oncol Rep · August 2016 OBJECTIVE: To determine the rate and performance of sentinel lymph node (SLN) mapping among women with high-risk endometrial cancers. METHODS: Patients diagnosed between 2012 and 2015 with uterine cancer of grade 3 endometrioid, clear cell, serous or carci ... Full text Link to item Cite

Is Intraperitoneal Chemotherapy Dead?

Journal Article Obstet Gynecol · June 2016 Full text Link to item Cite

Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis.

Journal Article Gynecol Oncol · January 2016 OBJECTIVE: To evaluate the association between body mass index (BMI) and mortality in women with endometrial cancer. METHODS: A systematic review was performed utilizing a Medline search with Mesh keywords 'endometrial neoplasms' and ('body mass index' or ... Full text Link to item Cite

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.

Journal Article J Immunother Cancer · 2016 BACKGROUND: CAN-003 was a randomized, open-label, Phase 2 trial evaluating the safety, efficacy and immune outcomes of CVac, a mucin 1 targeted-dendritic cell (DC) treatment as a maintenance therapy to patients with epithelial ovarian cancer (EOC). METHODS ... Full text Open Access Link to item Cite

The role of immune checkpoint inhibition in the treatment of ovarian cancer.

Journal Article Gynecol Oncol Res Pract · 2016 The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach. So far, emerging clinical data show limited clinical efficacy of these agents in ovarian cancer with ob ... Full text Link to item Cite

Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis.

Journal Article Gynecol Oncol Res Pract · 2016 BACKGROUND: Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however, tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro chemoresponse. METHODS: We conducted an a ... Full text Open Access Link to item Cite

Conservative management of morbidly adherent placenta: expert review.

Journal Article Am J Obstet Gynecol · December 2015 Over the last century, the incidence of placenta accreta, increta, and percreta, collectively referred to as morbidly adherent placenta, has risen dramatically. Planned cesarean hysterectomy at the time of cesarean delivery is the standard recommended trea ... Full text Link to item Cite

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Journal Article Gynecol Oncol · December 2015 BACKGROUND: To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). METHODS: A multicenter analysis of patients treated from 2004 to 2011 was performed. ... Full text Link to item Cite

A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

Journal Article Gynecol Oncol · November 2015 OBJECTIVE: To evaluate the use of adjuvant therapy after primary surgery for stage I-III uterine carcinosarcoma (CS). METHODS: A multi-institutional retrospective study of women with stage I-III CS was conducted. Analyses were stratified by stage (I/II and ... Full text Link to item Cite

Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.

Journal Article Gynecol Oncol · October 2015 OBJECTIVES: To identify angiogenic biomarkers associated with tumor angiogenesis and clinical outcome in high-grade serous ovarian cancer (HGSC). METHODS: 51 HGSC samples were analyzed using Affymetrix HG-U133A microarray. Microvessel density (MVD) counts ... Full text Link to item Cite

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.

Journal Article Gynecol Oncol · August 2015 OBJECTIVE: Type I epithelial ovarian cancers (EOCs) are reported to be relatively chemoresistant. This study sought to compare pretreatment chemoresponse assays in Type I vs. Type II EOCs. STUDY DESIGN: 383 women with stage III-IV EOC enrolled in an observ ... Full text Link to item Cite

Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer.

Journal Article Gynecol Oncol Rep · August 2015 OBJECTIVE: The Lumbee Indian tribe is the largest Native American tribe in North Carolina, with about 55,000 enrolled members who mostly reside in southeastern counties. We evaluated whether Lumbee heritage is associated with high-risk histologic subtypes ... Full text Link to item Cite

Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).

Journal Article Gynecol Oncol · June 2015 OBJECTIVE: The study objective was to examine the safety and cost savings of selective cardiac surveillance (CS) during treatment with pegylated liposomal doxorubicin (PLD). METHODS: A retrospective, dual institution study of women receiving PLD for the tr ... Full text Link to item Cite

Patient-reported outcomes as end points and outcome indicators in solid tumours.

Journal Article Nat Rev Clin Oncol · June 2015 Patient-reported outcome (PRO) measures, such as quality of life, have been associated with relevant clinical end points and are prognostic for survival outcomes in a variety of solid cancers in adults. In the past few years, PROs have garnered a greater i ... Full text Link to item Cite

Vaginal cuff thermal injury by mode of colpotomy at total laparoscopic hysterectomy: a randomized clinical trial.

Conference J Minim Invasive Gynecol · February 2015 STUDY OBJECTIVE: To evaluate if the use of Valleylab mode ("V mode") (Covidien, Mansfield, MA) electrothermal energy for colpotomy during total laparoscopic hysterectomy (LH) results in a smaller margin of thermal injury to the upper vagina compared with t ... Full text Link to item Cite

Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.

Journal Article Gynecol Oncol Res Pract · 2015 Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classification systems for ovarian cancer have proposed two ... Full text Link to item Cite

Patient preferences in advanced or recurrent ovarian cancer.

Journal Article Cancer · December 1, 2014 BACKGROUND: The objective of this study was to elucidate relative preferences of women with ovarian cancer for symptoms, treatment-related side effects, and progression-free survival (PFS) relevant to choosing a treatment regimen. METHODS: Women with advan ... Full text Link to item Cite

The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.

Journal Article Gynecol Oncol · November 2014 Antiangiogenic agents have demonstrated improved progression-free survival in women with primary and recurrent epithelial ovarian cancer (EOC). Biomarkers that predict outcomes in patients treated with antiangiogenic agents are being investigated to ration ... Full text Link to item Cite

A modified bipedicle VRAM flap for simultaneous reconstruction of a perineal and posterior vaginal defect

Journal Article Gynakologe · October 14, 2014 The management of locally advanced pelvic tumors regularly requires radical surgical resection. The resection results in significant intrinsic and extrinsic pelvic defects. The advent of composite flaps has revolutionized vaginal and perineal reconstructio ... Full text Cite

Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)

Conference Cancer Research · October 1, 2014 AbstractBackground: Epigenetic changes have been implicated in acquired resistance to platinum. SGI-110 is a second generation SQ HMA with improved pharmaceutical properties compared to decitabine. Here we r ... Full text Cite

SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.

Journal Article Gynecol Oncol · October 2014 OBJECTIVE: To explore and facilitate the multifaceted process of drug development and regulatory approval in ovarian cancer. METHODS: The Society of Gynecologic Oncology (SGO) recently sought and received input from multiple stakeholders including the Nati ... Full text Link to item Cite

A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.

Journal Article Am J Obstet Gynecol · July 2014 OBJECTIVE: Recurrence following primary platinum-based chemotherapy remains a challenge in the treatment of patients with advanced-stage epithelial ovarian cancer. This study examines whether a chemoresponse assay can identify patients who are platinum-res ... Full text Link to item Cite

Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.

Journal Article Cancer Treat Rev · May 2014 In the majority of cases, endometrial cancer is localized and highly curable through surgery and adjuvant radiotherapy. However, for patients with advanced or metastatic disease, prognosis is poor. Systemic treatments such as cytotoxic chemotherapy or horm ... Full text Link to item Cite

Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients.

Journal Article Gynecol Oncol · May 2014 OBJECTIVE: The aim of this study is to determine whether a minimally invasive approach to hysterectomy is associated with an increased rate of lymph vascular space invasion (LVSI) and/or malignant pelvic peritoneal cytology in endometrial cancer. METHODS: ... Full text Link to item Cite

Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer.

Journal Article Int J Gynecol Cancer · May 2014 OBJECTIVE: The objective of this study was to evaluate prognostic risk factors for survival in women with low-grade serous epithelial ovarian cancer (LGSC). METHODS: A multicenter retrospective analysis of patients with LGSC was conducted. Potential epidem ... Full text Link to item Cite

The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance.

Journal Article Gynecol Oncol · April 2014 BACKGROUND: We examined the distribution of obesity, diabetes, and race in Type I and Type II endometrial cancers (EC) and their associations with clinical outcomes. METHODS: A multi-institutional retrospective analysis of Type I and II EC cases from Janua ... Full text Link to item Cite

A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.

Journal Article Gynecol Oncol · March 2014 OBJECTIVE: To develop a nomogram to predict overall survival (OS) in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. METHODS: A multicenter retrospective study was conducted. Potential prognostic variables included age; stage ... Full text Link to item Cite

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.

Journal Article Gynecol Oncol · March 2014 OBJECTIVE: To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. METHODS: Eligible pat ... Full text Link to item Cite

Metformin is associated with improved survival in endometrial cancer.

Journal Article Gynecol Oncol · February 2014 OBJECTIVE: Preclinical evidence suggests that metformin exhibits anti-tumorigenic effects in endometrial cancer. We sought to investigate the association of metformin on endometrial cancer outcomes. METHODS: A multi-institutional IRB-approved retrospective ... Full text Link to item Cite

Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.

Journal Article Int J Gynecol Cancer · February 2014 PURPOSE: This study aimed to explore the activity of dasatinib in combination with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells. METHODS: Cells with previously determined SRC pathway and protein expression (SRC pathway/SRC pro ... Full text Link to item Cite

Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: a case report.

Journal Article Int J Gynecol Pathol · January 2014 We describe clinicopathologic and immunohistochemical features of an unusual case of cystic fibrosis manifesting in the cervix as a mass lesion, mimicking cervical adenocarcinoma. A 24-year-old nulligravida with cystic fibrosis developed heavy postcoital v ... Full text Link to item Cite

Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.

Journal Article Int J Womens Health · 2014 Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently, clinical trials have focused on novel antiangiogenic agents in combination with chemotherapy or alone in women with primary and recurrent ovarian cancer. Antiangiogenic agen ... Full text Open Access Link to item Cite

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.

Journal Article Front Oncol · 2014 OBJECTIVES: Underlying mechanisms regulating angiogenesis in ovarian cancer have not been completely elucidated. Evidence suggests that the TP53 tumor suppressor pathway and tumor microenvironment play integral roles. We utilized microarray technology to s ... Full text Link to item Cite

Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines.

Journal Article Gynecol Oncol Res Pract · 2014 BACKGROUND: To explore the activity of dasatinib alone and in combination with gemcitabine and docetaxel in uterine leiomyosarcoma (uLMS) cell lines, and determine if dasatinib inhibits the SRC pathway. METHODS: SK-UT-1 and SK-UT-1B uLMS cells were treated ... Full text Open Access Link to item Cite

Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?

Journal Article Gynecol Oncol · December 2013 OBJECTIVES: To examine whether adjuvant therapy after primary surgery for treatment of early-stage uterine leiomyosarcoma (LMS) improves recurrence and survival rates. METHODS: A multisite, retrospective study of women diagnosed with stage I-II high grade ... Full text Link to item Cite

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.

Journal Article Cancer · October 15, 2013 BACKGROUND: The objective of this study was to evaluate the comparative effectiveness of strategies that incorporated bevacizumab into the primary platinum-based treatment of ovarian cancer: 1) no bevacizumab; 2) concurrent and maintenance bevacizumab for ... Full text Link to item Cite

Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.

Journal Article J Cancer Res Clin Oncol · October 2013 PURPOSE: CA-125 has been a valuable marker for detecting ovarian cancer, however, it is not sensitive enough to detect early-stage disease and not specific to ovarian cancer. The purpose of our study was to identify autoantibody markers that are specific t ... Full text Link to item Cite

Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.

Journal Article Gynecol Oncol · September 2013 OBJECTIVE: To determine if early palliative care intervention in patients with recurrent, platinum-resistant ovarian cancer is potentially cost saving or cost-effective. METHODS: A decision model with a 6 month time horizon evaluated routine care versus ro ... Full text Link to item Cite

Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer.

Journal Article Gynecol Oncol · July 2013 OBJECTIVES: (1) To describe the prevalence, timing and setting of documented end-of-life (EOL) discussions in patients with advanced ovarian cancer; and (2) to assess the impact of timing and setting of documented end-of-life discussions on EOL quality car ... Full text Link to item Cite

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Journal Article Gynecol Oncol · July 2013 OBJECTIVE: We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. METHODS: Eligible patients had persistent or recurrent cervical cancer not amenable ... Full text Link to item Cite

Image-guided brachytherapy for gynecologic surgeons.

Journal Article Surg Oncol Clin N Am · July 2013 Brachytherapy is a fundamental component of the definitive treatment of many advanced gynecologic malignancies, most notably cancers of the uterine corpus and cervix, and allows high radiation doses to be delivered to the target while minimizing the normal ... Full text Link to item Cite

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

Journal Article Gynecol Oncol · July 2013 OBJECTIVES: The efficacy and safety of bevacizumab and docetaxel were evaluated in women who developed recurrent epithelial ovarian, fallopian, or peritoneal cancer within 12 months of platinum-based therapy. METHODS: Patients received docetaxel (40 mg/m(2 ... Full text Link to item Cite

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.

Journal Article Int J Gynecol Cancer · June 2013 OBJECTIVES: (1) To determine whether use of a PARP inhibitor or (2) BRCA1/2 mutation testing followed by a PARP inhibitor for test positives is potentially cost-effective for maintenance treatment of platinum-sensitive recurrent high-grade serous ovarian c ... Full text Link to item Cite

The impact of diabetes and obesity on endometrial cancer outcomes

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2013 Link to item Cite

Abstract 330A: Differential expression of angiogenic genes in invasive high grade serous ovarian carcinomas.

Conference Cancer Research · April 15, 2013 AbstractOur objective is to establish quantifiable and reproducible biomarkers that can aid in prognosis, and predicting treatment outcome in invasive high-grade serous ovarian cancer (HGSC). The goal of thi ... Full text Cite

Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.

Journal Article Gynecol Oncol · April 2013 OBJECTIVE: There is limited information concerning the role of relative dose intensity (RDI) on clinical outcomes in solid tumors. The objectives of our study were to evaluate the prognostic significance of RDI and predictors of reduced RDI in women with n ... Full text Link to item Cite

A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.

Journal Article Gynecol Oncol · January 2013 OBJECTIVE: To determine if there is an advantage to combination chemotherapy and radiation for optimally resected stage IIIC endometrial cancer (EC). METHODS: A multicenter retrospective analysis of patients with EC from 1991 to 2008 was conducted. Inclusi ... Full text Link to item Cite

BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.

Journal Article Am J Surg Pathol · January 2013 BRCA1 and BRCA2 dysfunction, frequently seen in high-grade serous ovarian carcinomas, often results from germline mutations, somatic mutations, and promoter methylation. Identification of tumors with BRCA defects has therapeutic and prognostic implications ... Full text Link to item Cite

Metastatic adenocarcinoma after laparoscopic supracervical hysterectomy with morcellation: A case report.

Journal Article Gynecol Oncol Case Rep · 2013 •Uterine morcellation is common in minimally invasive hysterectomy but should be performed with caution due to risk of unsuspected malignancy.•Intraoperative techniques should be considered to minimize dissemination of endometrial tissue during morcellatio ... Full text Link to item Cite

TP53 Status is Associated with Thrombospondin1 Expression In vitro.

Journal Article Front Oncol · 2013 OBJECTIVES: To elucidate the association between thrombospondin1 (THBS1) expression and TP53 status and THBS1 promoter methylation in epithelial ovarian cancer (EOC). METHODS: Epithelial ovarian cancer cell lines with known TP53 status were analyzed for TH ... Full text Link to item Cite

Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery.

Journal Article J Clin Oncol · December 2012 201 Background: The Federation of Gynecology and Obstetrics (FIGO) staging system and the National Comprehensive Cancer Network (NCCN) guidelines for endometrial cancer recommend performing pelvic peritoneal cytology to look for the presence of cancer cell ... Full text Link to item Cite

Surgical staging for endometrial cancer in the elderly - Is there a role for lymphadenectomy?

Journal Article Obstetrical and Gynecological Survey · November 1, 2012 Full text Cite

A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.

Journal Article Clin Cancer Res · October 1, 2012 PURPOSE: We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in the treatment of advanced and recurrent epithelial ovarian cancer. EXPERIMENTAL DESIGN: The primary objectiv ... Full text Link to item Cite

A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.

Journal Article Gynecol Oncol · October 2012 OBJECTIVE: To evaluate the impact of adjuvant post-operative therapy in women with early stage uterine carcinosarcoma. METHODS: After IRB approval was obtained at all sites, a multi-center retrospective study of women with FIGO stage I-II uterine carcinosa ... Full text Link to item Cite

Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.

Journal Article Gynecol Oncol · September 2012 OBJECTIVE: To estimate the activity and tolerability of iniparib plus paclitaxel and carboplatin as initial therapy of uterine carcinosarcoma. METHODS: Eligible patients had advanced, persistent or recurrent carcinosarcoma of the uterus, measurable disease ... Full text Link to item Cite

Physical strain and urgent need for ergonomic training among gynecologic oncologists who perform minimally invasive surgery.

Journal Article Gynecol Oncol · September 2012 OBJECTIVES: There is limited data regarding physical strain and minimally invasive gynecologic surgery (MIS). We sought to evaluate ergonomic strain among gynecologic oncologists. METHODS: An online survey was sent to all physician members of the Society o ... Full text Link to item Cite

Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers.

Journal Article Gynecol Oncol · August 2012 OBJECTIVE: The study aim was to compare outcomes in women with high-grade endometrial cancer (EC) who underwent surgical staging via minimally invasive surgery (MIS) versus laparotomy. METHODS: This is a retrospective, multi-institutional cohort study of p ... Full text Link to item Cite

Obesity: Too big a problem to ignore.

Journal Article Gynecol Oncol · August 2012 Full text Link to item Cite

Quinary debulking for epithelial ovarian cancer.

Journal Article J Surg Case Rep · July 1, 2012 We report a case of optimal quinary debulking for recurrent papillary serous carcinoma of the ovary involving the liver parenchyma through the full thickness of the diaphragm into the lung parenchyma. Multiple debulking procedures for ovarian cancer are co ... Full text Link to item Cite

Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?

Journal Article Gynecol Oncol · July 2012 OBJECTIVES: We sought to evaluate the effect of systematic lymphadenectomy (LND) on endometrial cancer-specific survival in an elderly population. METHODS: Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) program from 1988 to ... Full text Link to item Cite

A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

Journal Article Cancer · July 1, 2012 BACKGROUND: The aim of this randomized clinical trial was to evaluate the efficacy and safety of combination (cDC) and sequential (sDC) weekly docetaxel and carboplatin in women with recurrent platinum-sensitive epithelial ovarian cancer (EOC). METHODS: Pa ... Full text Link to item Cite

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

Journal Article Cancer Chemother Pharmacol · July 2012 PURPOSE: Preclinical data suggest concurrent inhibition of VEGF, mTOR and EGFR pathways may augment antitumor and antiangiogenic effects compared to inhibition of each pathway alone. This study evaluated the maximum tolerated dose/recommended phase II dose ... Full text Link to item Cite

Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.

Journal Article Gynecol Oncol · June 2012 OBJECTIVE: To identify factors that increase the risk of neutropenic events in women with advanced ovarian carcinoma receiving initial chemotherapy. METHODS: Multi-center retrospective study of women with FIGO stage III-IV epithelial ovarian cancer treated ... Full text Link to item Cite

The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer.

Journal Article Int J Radiat Oncol Biol Phys · April 1, 2012 BACKGROUND: The appropriate uses of lymph node dissection (LND) and adjuvant radiation therapy (RT) for Stage I endometrial cancer are controversial. We explored the impact of specific RT modalities (whole pelvic RT [WPRT], vaginal brachytherapy [VB]) and ... Full text Link to item Cite

Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.

Journal Article Int J Gynecol Cancer · March 2012 OBJECTIVE: The purpose of this review was to provide an overview of angiogenesis, including the rationale for targeting angiogenesis as a treatment strategy for epithelial ovarian cancer (EOC) and to discuss available clinical trial data with antiangiogeni ... Full text Link to item Cite

Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.

Journal Article Cancer · January 15, 2012 BACKGROUND: In a randomized controlled trial (RCT) of patients with recurrent, platinum-sensitive ovarian cancer, the combination weekly docetaxel and carboplatin was associated a with progression-free survival (PFS) of 13.7 months compared with 8.4 months ... Full text Link to item Cite

Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.

Journal Article Gynecol Oncol · December 2011 OBJECTIVES: A phase II clinical trial compared docetaxel in combination with carboplatin to sequential single agent docetaxel followed by carboplatin for treatment of recurrent platinum-sensitive ovarian, peritoneal, or tubal cancer. This manuscript report ... Full text Link to item Cite

The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.

Journal Article Gynecol Oncol · November 2011 OBJECTIVES: To elucidate the regulation of MASPIN expression in epithelial ovarian cancer (EOC) and associations with p53 status and MASPIN promoter methylation. METHODS: Seven EOC cell lines and 110 advanced stage EOC specimens were analyzed for MASPIN pr ... Full text Link to item Cite

Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma.

Journal Article Gynecol Oncol · October 2011 OBJECTIVE: To validate the Mayo algorithm to intraoperatively identify women with endometrial cancer in whom lymphadenectomy may be safely omitted. METHODS: A multi-center retrospective chart review 1977-2010 was completed using two independent institution ... Full text Link to item Cite

Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.

Journal Article Gynecol Oncol · September 2011 OBJECTIVE: To evaluate the costs and effectiveness of thromboprophylaxis strategies following laparotomy for ovarian cancer. METHODS: We constructed a decision model to evaluate six strategies for management of postoperative venous thromboembolism (VTE) ri ... Full text Link to item Cite

Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer.

Journal Article Am J Obstet Gynecol · August 2011 OBJECTIVE: The objective of the study was to compare adverse event rates between laparoscopic vs open surgery for endometrial cancer. STUDY DESIGN: This was a retrospective cohort study comparing 107 women who underwent laparoscopy with 269 age- and body m ... Full text Link to item Cite

Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer.

Journal Article J Clin Oncol · May 20, 2011 5084 Background: Although considerable progress has been made in the treatment of advanced ovarian cancer, complications of both disease and treatment limit long term survival. Further research is needed on specific patient- and treatment-related factors t ... Link to item Cite

MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.

Journal Article Clin Cancer Res · May 15, 2011 PURPOSE: The purpose of this study is to test whether peptide epitopes chosen from among those naturally processed and overpresented within MHC molecules by malignant, but not normal cells, when formulated into cancer vaccines, could activate antitumor T-c ... Full text Link to item Cite

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.

Journal Article Gynecol Oncol · April 2011 PURPOSE: To explore the activity of dasatinib alone and in combination with paclitaxel and carboplatin in ovarian cancer cells and to determine if dasatinib activity can be predicted based on evaluation of the SRC pathway. EXPERIMENTAL DESIGN: Microarray a ... Full text Link to item Cite

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.

Journal Article Clin Exp Immunol · March 2011 Selection of suitable antigens is critical for the development of cancer vaccines. Most desirable are over-expressed cell surface proteins that may serve as targets for both antibodies and T cells, thus maximizing a concerted immune response. Towards this ... Full text Link to item Cite

Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study.

Journal Article J Clin Oncol · March 1, 2011 PURPOSE: There is no consensus on the best regimen for the primary treatment of low-risk gestational trophoblastic neoplasia (GTN). PATIENTS AND METHODS: Two commonly used single-drug regimens were compared with respect to the proportion of patients meetin ... Full text Link to item Cite

Recurrent granulosa cell tumor presenting with spontaneous retroperitoneal hemorrhage: A case report.

Journal Article Gynecol Oncol Case Rep · 2011 ► Patients diagnosed with granulosa cell tumor require long-term surveillance. ► Recurrent granulosa cell tumor may present as spontaneous retroperitoneal hemorrhage. ► We present an unusual case of recurrent granulosa cell tumor resulting in retroperitone ... Full text Link to item Cite

Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy.

Journal Article Gynecol Oncol Case Rep · 2011 ► Bevacizumab may increase the risk of mucosal ulceration and subsequent bone necrosis. ► Patients receiving bevacizumab should be closely monitored for dental symptoms. ... Full text Link to item Cite

Antiangiogenic therapies in epithelial ovarian cancer.

Journal Article Cancer Control · January 2011 BACKGROUND: Angiogenesis is a critical component of tumor development and proliferation, and increased angiogenesis has been associated with a worse clinical outcome in a number of solid tumors, including ovarian cancer. Therefore, agents that target the a ... Full text Link to item Cite

A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.

Journal Article Gynecol Oncol · August 1, 2010 BACKGROUND: The objective of this study was to estimate antitumor activity and toxicity of weekly docetaxel and gemcitabine as second-line chemotherapy for patients with recurrent uterine carcinosarcoma. METHODS: Patients with recurrent carcinosarcoma of t ... Full text Link to item Cite

Expression signatures of TP53 mutations in serous ovarian cancers.

Journal Article BMC Cancer · May 26, 2010 BACKGROUND: Mutations in the TP53 gene are extremely common and occur very early in the progression of serous ovarian cancers. Gene expression patterns that relate to mutational status may provide insight into the etiology and biology of the disease. METHO ... Full text Open Access Link to item Cite

Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.

Journal Article Int J Cancer · March 15, 2010 We previously found that the gene encoding the Myelin and Lymphocyte protein, MAL, was among the most highly expressed genes in serous ovarian cancers from short-term survivors (<3 years) relative to those of long-term survivors (>7 years). In the present ... Full text Link to item Cite

Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.

Journal Article Gynecol Oncol · January 2010 OBJECTIVE: To study patterns of recurrence and survival outcomes in patients with surgical stage I, grade 3 endometrioid adenocarcinoma of the endometrium (EA) treated with various treatment modalities. METHODS: A retrospective multi-institutional study of ... Full text Link to item Cite

Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.

Journal Article Gynecol Oncol · December 2009 OBJECTIVES: The Gynecologic Oncology Group (GOG) examined the association between the relative expression of the DeltaNp63alpha isoform and clinicopathologic variables, p53 status, angiogenic markers, progression-free survival (PFS) and overall survival (O ... Full text Link to item Cite

An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

Journal Article Gynecol Oncol · November 2009 OBJECTIVES: Stage I-II uterine papillary serous carcinoma (UPSC) patients have a significant risk for extrapelvic recurrence. However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic ... Full text Link to item Cite

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.

Journal Article Gynecol Oncol · November 2009 PURPOSE: To estimate antitumor activity and toxicity of weekly topotecan hydrochloride in patients with persistent or recurrent cervical carcinoma who failed prior treatment. PATIENTS AND METHODS: Women entered on study had or failed one prior chemotherapy ... Full text Link to item Cite

Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.

Journal Article J Immunother · October 2009 Immunotherapeutic vaccine is potentially an effective strategy to combat cancer. Essential components of an effective vaccine must include antigens that are processed by the major histocompatibility complex class I pathway, presented by the tumor major his ... Full text Link to item Cite

Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review.

Journal Article J Pain Symptom Manage · September 2009 The safety and efficacy of indwelling intraperitoneal (IP) catheters for the management of refractory malignant ascites is unclear. A systematic literature overview and retrospective chart review of patients with malignant refractory ascites who underwent ... Full text Link to item Cite

A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.

Journal Article Gynecol Oncol · September 2009 OBJECTIVES: The appropriate sequencing of chemotherapy and radiation for the treatment of advanced endometrial cancer has not yet been determined. We sought to evaluate the outcome and adverse effects in patients with advanced stage endometrial cancer trea ... Full text Link to item Cite

Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.

Journal Article Gynecol Oncol · August 2009 OBJECTIVE: To determine factors related to recurrence and survival in women with stage IIIA endometrial cancer; to examine outcomes of women with IIIA1 disease. METHODS: Multi-institutional analysis of women with stage IIIA endometrial carcinoma undergoing ... Full text Link to item Cite

Effect of treatment of patients with early-stage uterine carcinosarcoma.

Journal Article J Clin Oncol · May 20, 2009 5516 Background: The treatment of early stage uterine carcinosarcoma is controversial. We sought to retrospectively review factors that influence progression and survival. METHODS: A retrospective, multi-institution study of women diagnosed from 1997-2007 ... Link to item Cite

Effect of treatment of patients with early-stage uterine carcinosarcoma

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2009 Link to item Cite

Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.

Journal Article Clin Cancer Res · April 1, 2009 PURPOSE: Although few women with advanced serous ovarian cancer are cured, detection of the disease at an early stage is associated with a much higher likelihood of survival. We previously used gene expression array analysis to distinguish subsets of advan ... Full text Link to item Cite

Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.

Journal Article Int J Gynecol Cancer · April 2009 OBJECTIVE: To assess the attitudes regarding the use of colony-stimulating factor (CSF) and the maintenance of relative dose intensity (RDI) by gynecologic oncologists during the administration of chemotherapy to patients with epithelial ovarian cancer. ME ... Full text Link to item Cite

Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.

Journal Article Gynecol Oncol · March 2009 OBJECTIVES: The aims of this study were to examine prognostic significance of microvessel density (MVD) in previously-untreated, advanced epithelial ovarian cancer (EOC) and explore associations between MVD and factors that affect angiogenesis. METHODS: MV ... Full text Link to item Cite

The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma.

Journal Article Gynecol Oncol · March 2009 OBJECTIVE: We sought to assess the accuracy of a preoperative grade 1 designation and role of lymphadenectomy in women with preoperative grade 1 endometrial cancer. METHODS: A retrospective analysis of patients diagnosed with preoperative grade 1 endometri ... Full text Link to item Cite

Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.

Journal Article Gynecol Oncol · March 2009 OBJECTIVES: To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT). METHODS: ... Full text Link to item Cite

Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program.

Journal Article JSLS · 2009 BACKGROUND AND OBJECTIVE: The robotic surgical platform is an alternative technique to traditional laparoscopy and requires the development of new surgical skills for both the experienced surgeon and trainee. Our goal was to perform an early evaluation of ... Full text Link to item Cite

Relationship between tamoxifen use and high risk endometrial cancer histologic types.

Journal Article Gynecol Oncol · January 2009 OBJECTIVES: We wished to determine whether a pre-existing diagnosis of breast cancer or the use of tamoxifen among patients with pre-existing breast cancer influences the histologic type of subsequently diagnosed endometrial carcinoma, the interval between ... Full text Link to item Cite

A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.

Journal Article Gynecol Oncol · December 2008 OBJECTIVES: To estimate the anti-tumor activity and toxicity of paclitaxel poliglumex (PPX) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (EOC) in second or third line treatment. METHOD: Twenty-five patients ... Full text Link to item Cite

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Journal Article J Clin Oncol · September 1, 2008 PURPOSE: To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally resected stage III ovarian cancer. PATIENTS AND METHODS: A decision model was developed to compare the cost effectiveness at 7-, ... Full text Link to item Cite

Medical and surgical treatment of placenta percreta to optimize bladder preservation.

Journal Article Obstet Gynecol · August 2008 BACKGROUND: Placenta percreta is associated with significant morbidity and mortality. Interventions are dictated by hemodynamic stability, desire to retain future fertility, and efforts to reduce surgical morbidity at time of delivery. CASES: Two cases of ... Full text Link to item Cite

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.

Journal Article Gynecol Oncol · March 2008 PURPOSE: This phase II trial assessed the activity and tolerability of cetuximab (C225, Erbitux) in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma. PATIENTS AND METHODS: Patients were to re ... Full text Link to item Cite

Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer.

Journal Article Biomark Insights · February 1, 2008 Tumor hypoxia is associated with adverse outcome in many malignancies. The goal of this study was to determine if elevated expression of carbonic anhydrase IX (CAIX), a biomarker of hypoxia, predicts for recurrence in early-stage cervical cancer. The chart ... Full text Link to item Cite

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.

Journal Article Int J Gynecol Cancer · 2008 While bevacizumab has shown activity in recurrent ovarian cancer, a higher than expected incidence of bowel perforations has been reported in recent trials. We sought to determine factors associated with toxicity and tumor response in patients with relapse ... Full text Link to item Cite

Desmoplastic small round cell tumor masquerading as advanced ovarian cancer.

Journal Article Int J Gynecol Cancer · 2008 Desmoplastic small round cell tumor (DSRCT) is a rare abdominal malignancy usually diagnosed in young adult males. Most patients have widespread disease at presentation, with an organ of origin difficult to ascertain. A 33-year-old female presented to her ... Full text Link to item Cite

Cervical cancer.

Journal Article J Natl Compr Canc Netw · January 2008 Full text Link to item Cite

Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis.

Journal Article Gynecol Oncol · December 2007 OBJECTIVES: To estimate the relative cost-effectiveness of treatments for patients with FIGO stage IB2 cervical cancer and no evidence of metastasis as determined by combination of positron emission tomography/computed tomography (PET/CT). METHODS: A Marko ... Full text Link to item Cite

The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.

Journal Article Gynecol Oncol · November 2007 OBJECTIVE: : The optimal adjuvant therapy for women with stages III and IV endometrial cancer following surgical staging and cytoreductive surgery is controversial. We sought to determine the outcome of patients with advanced stage endometrial cancer treat ... Full text Link to item Cite

Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

Journal Article Gynecol Oncol · November 2007 OBJECTIVE: We wished to compare the cost-effectiveness of three chemotherapy regimens for treatment of recurrent platinum-sensitive ovarian cancer. METHODS: A Markov decision tree was constructed comparing three chemotherapy regimens: (1) carboplatin alone ... Full text Link to item Cite

Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.

Journal Article Gynecol Oncol · August 2007 OBJECTIVES: Endometrial cancer is the most common gynecologic malignancy in the United States. Adjuvant radiotherapy in patients with intermediate risk disease (stage IB, IC, and occult stage II) is controversial. Despite no proven survival advantage, a si ... Full text Link to item Cite

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Journal Article J Clin Oncol · July 1, 2007 PURPOSE: Ovarian cancer (OC) patients experiencing progressive disease (PD) within 6 months of platinum-based therapy in the primary setting are considered platinum resistant (Pt-R). Currently, pegylated liposomal doxorubicin (PLD) is a standard of care fo ... Full text Link to item Cite

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.

Journal Article Gynecol Oncol · July 2007 OBJECTIVES: The aim of this study was to explore the co-expression and prognostic relevance of thrombospondin-1 (THBS-1), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR-1) in epithelial ovarian c ... Full text Link to item Cite

Outcomes in surgical stage I uterine papillary serous carcinoma.

Journal Article Gynecol Oncol · June 2007 OBJECTIVE: The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to determine whether outcomes of women with surgical stage I UPSC differ with and without adjuvant therapy. METHODS: Retrospective mu ... Full text Link to item Cite

Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.

Journal Article Int J Clin Oncol · February 2007 BACKGROUND: The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies. METHODS: Patients had measurable disease defined by clinical examination or radiographic stu ... Full text Link to item Cite

The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.

Journal Article Gynecol Oncol · February 2007 OBJECTIVE: The clinical significance and optimal management of patients with stage IIIA endometrial cancer are controversial. We sought to determine whether recurrence and survival of patients with stage IIIA endometrial cancer differ with surgical patholo ... Full text Link to item Cite

Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.

Journal Article Int J Gynecol Cancer · 2007 The objective of this study was to evaluate the treatment outcomes and risk factors of women with surgical stage I endometrial adenocarcinoma who were initially treated with surgery alone and subsequently developed isolated vaginal recurrences. Patients wi ... Full text Link to item Cite

Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity.

Journal Article Int J Gynecol Cancer · 2007 To compare flap-specific complications of gracilis myocutaneous (GM) and rectus abdominis myocutaneous (RAM) flap neovaginal reconstructions after radical pelvic surgery. The study was a single-institution retrospective review of patients undergoing concur ... Full text Link to item Cite

68

Conference International Journal of Radiation Oncology*Biology*Physics · November 2006 Full text Cite

Targeted bio weapons in the war against gynecologic cancers

Journal Article Contemporary Ob/Gyn · October 1, 2006 Will biological warfare revolutionize the battle against gynecologic cancers? Two experts share the latest molecular tactics using "special" agents. Lethal weapons like Herceptin can throw up some roadblocks, even when they can't always destroy a tumor. ... Cite

Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.

Journal Article Gynecol Oncol · July 2006 OBJECTIVE: To determine whether pelvic lymph node count is associated with patterns of recurrence or survival in patients with FIGO stage I and II endometrial cancer. METHODS: Single institution retrospective study of 467 patients with FIGO stage I and II ... Full text Link to item Cite

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.

Journal Article Gynecol Oncol · June 2006 Featured Publication OBJECTIVE: This study examined MASPIN expression in human ovarian cancer, and explored the association between MASPIN and prognosis in patients with advanced stage disease treated with first-line cisplatin, carboplatin and/or paclitaxel. METHODS: Frozen pr ... Full text Link to item Cite

Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.

Journal Article Int J Hyperthermia · March 2006 The study was designed to determine the maximum tolerated dose (MTD) of IP cisplatin [CDDP] combined with intravenous thiosulphate and concurrent whole abdomen hyperthermia for advanced, recurrent or progressive ovarian carcinoma. Between September 1991 an ... Full text Link to item Cite

Use of trastuzumab in the treatment of metastatic endometrial cancer.

Journal Article Int J Gynecol Cancer · 2006 Systemic therapy of metastatic endometrial cancer is relatively ineffective. Response rates to chemotherapy and hormonal therapy in published studies range from 11% to 57%, but most responses are partial and of limited duration. In this case, we present a ... Full text Link to item Cite

Tissue transglutaminase expression in early-stage cervical cancer

Conference INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS · 2006 Full text Cite

Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.

Journal Article Gynecol Oncol · December 2005 OBJECTIVE: Surgical staging of endometrial cancer identifies those patients with microscopic metastatic disease most likely to benefit from adjuvant therapy and may also confer therapeutic benefit. Our objective was to compare survival of patients who unde ... Full text Link to item Cite

Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.

Journal Article J Clin Oncol · June 1, 2005 PURPOSE: Selective lymphadenectomy is widely accepted in the management of endometrial cancer. Purported benefits are individualization of adjuvant therapy based on extent of disease and resection of occult metastases. Our goal was to assess effects of the ... Full text Link to item Cite

Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.

Journal Article Int J Hyperthermia · June 2005 OBJECTIVE: A phase I/II study of Doxil combined with whole abdomen hyperthermia was conducted in patients with refractory ovarian cancer. Liposomal doxorubicin combined with hyperthermia has been shown to increase both liposomal delivery and drug extravasa ... Full text Link to item Cite

Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin.

Journal Article Int J Hyperthermia · June 2005 PURPOSE: Prospective assessment of quality of life (QoL) in patients with refractory, residual or recurrent ovarian cancer receiving whole abdomen hyperthermia and intravenous liposomal doxorubicin chemotherapy. METHODS: Treatment consisted of six cycles o ... Full text Link to item Cite

Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity.

Journal Article Gynecol Oncol · May 2005 PURPOSE: To compare flap-specific complications of rectus abdominis myocutaneous (RAM) and myoperitoneal (RAMP) flap neovagina reconstructions performed concurrently with radical pelvic procedures. MATERIALS AND METHODS: Retrospective single institution ch ... Full text Link to item Cite

Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery.

Journal Article Int J Gynecol Cancer · 2005 The objective of this article is to compare the flap-specific complications associated with vertical (VRAM) and transverse (TRAM) rectus abdominis myocutaneous flap vaginal reconstructions performed during radical pelvic procedures. A retrospective chart r ... Full text Link to item Cite

Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer.

Journal Article J Clin Oncol · July 15, 2004 5089 Background: A phase I/II study of liposomal doxorubicin combined with whole abdominal hyperthermia was conducted in patients with refractory ovarian cancer. Liposomal doxorubicin combined with hyperthermia has been shown to increase liposomal extravas ... Link to item Cite

Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer.

Journal Article J Clin Oncol · July 15, 2004 5152 Background: Topotecan (T) and vinorelbine (V) have shown efficacy in recurrent ovarian and cervical cancer. The purpose of this trial was to determine the recommended dose of combination T and V and to assess its efficacy in patients with refractory g ... Link to item Cite

The role of optimal debulking in advanced stage serous carcinoma of the uterus.

Journal Article Gynecol Oncol · July 2004 OBJECTIVE: To evaluate the role of optimal surgical cytoreduction and postoperative therapy in women with advanced uterine serous carcinoma (USC). METHODS: A multi-institutional, retrospective review identified 52 women with stage IV USC. Patient factors, ... Full text Link to item Cite

The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.

Journal Article Gynecol Oncol · July 2004 OBJECTIVE: To assess if the angiogenic factors vascular endothelial growth factor (VEGF) and D-dimer are predictive of persistent disease, early relapse, and survival in patients with ovarian cancer who achieve a complete clinical remission after first-lin ... Full text Link to item Cite

Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.

Journal Article Gynecol Oncol · May 2004 OBJECTIVE: We wished to evaluate survival and adverse outcomes of patients with stage IB2 cervical cancer treated primarily with radical hysterectomy and lymphadenectomy. METHODS: A review was performed of all patients undergoing primary radical hysterecto ... Full text Link to item Cite

Abdominal pain and bloating in two 20-something patients

Journal Article Contemporary Ob/Gyn · December 1, 2003 Cite

High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease.

Journal Article Gynecol Oncol · October 2003 BACKGROUND: Patients with pelvic sidewall recurrences of cervical cancer have a dismal prognosis. Intraoperative radiation therapy (IORT) has demonstrated encouraging results. Patients have traditionally been excluded from IORT if they had distant metastas ... Full text Link to item Cite

Platinum-resistant and refractory ovarian cancer: Second-line treatment options

Journal Article American Journal of Cancer · September 8, 2003 Despite an initial response rate of greater than 70% to platinum-based chemotherapy, most patients with advanced epithelial ovarian cancer eventually develop and succumb to recurrent disease. Ovarian cancer patients with platinum-resistant and -refractory ... Full text Cite

A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma.

Journal Article Cancer · July 15, 2003 BACKGROUND: Five randomized studies have demonstrated a benefit derived from adding cisplatin (CDDP)-based chemotherapy to radiotherapy (RT) for treatment of cervical carcinoma. The Dutch Phase III pelvic tumor trial demonstrated a survival and local contr ... Full text Link to item Cite

The role of PET scanning in the detection of recurrent cervical cancer.

Journal Article Gynecol Oncol · July 2003 OBJECTIVES: [(18)F] Fluoro-2-deoxyglucose positron emission tomography (FDG PET) has recently been established as a sensitive and specific method of detecting lymph node metastases in newly diagnosed cervical cancer. Little is known about the efficacy of P ... Full text Link to item Cite

Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.

Journal Article Gynecol Oncol · January 2003 OBJECTIVES: Weekly paclitaxel alone has moderate activity in the salvage treatment of recurrent ovarian cancer and is associated with a favorable toxicity profile. Combination paclitaxel and carboplatin is a well-established first-line regimen for ovarian ... Full text Link to item Cite

Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.

Journal Article Gynecol Oncol · December 2001 OBJECTIVE: The aim of this study was to test the hypothesis that p53 mutations are less frequent in ovarian cancers with alterations in other genes that regulate G1 progression. METHODS: Expression of G1 stimulatory (cyclins D1 and E, cdk4, Ki67) and inhib ... Full text Link to item Cite

Mycobacterium bovis peritonitis mimicking ovarian cancer in a young woman.

Journal Article Clin Infect Dis · August 15, 2001 We describe a 27-year-old woman with peritonitis due to Mycobacterium bovis that initially appeared to be ovarian cancer. Clinicians should include this disease in the differential diagnosis of ovarian cancer and should consider laparoscopic diagnosis in t ... Full text Link to item Cite

Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.

Journal Article Gynecol Oncol · August 2001 OBJECTIVE: The regulation of the metastatic process in epithelial ovarian cancer has not been well defined. Similar to other tumor types, the angiogenic phenotype in ovarian cancer strongly influences clinical outcome, suggesting that the acquisition of a ... Full text Link to item Cite

Allele loss on chromosome 1p36 in epithelial ovarian cancers.

Journal Article Gynecol Oncol · July 2001 OBJECTIVES: Prior studies have shown that allelic loss on chromosome 1p36 occurs frequently in ovarian as well as several other types of cancer. This suggests that inactivation of gene(s) in this region may play a role in the pathogenesis of these cancers. ... Full text Link to item Cite

Favorable survival associated with microsatellite instability in endometrioid endometrial cancers.

Journal Article Obstet Gynecol · March 2001 OBJECTIVE: To determine whether microsatellite instability in endometrioid endometrial cancer is associated with favorable survival. METHODS: Microsatellite instability analysis was performed in 131 patients with endometrioid endometrial cancer using three ... Full text Link to item Cite

Vacuum-assisted closure for cutaneous gastrointestinal fistula management.

Journal Article Gynecol Oncol · March 2001 BACKGROUND: Cutaneous gastrointestinal (GI) fistulas are a challenging complication in the oncologic patient population. The fistulous effluent is difficult to manage and adversely alters quality of life. Nonsurgical management of enteric fistulas is succe ... Full text Link to item Cite

K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.

Journal Article Gynecol Oncol · February 2001 OBJECTIVE: Müllerian inclusion cysts (MIC) are small benign appearing glands that are occasionally noted in lymph nodes and peritoneal biopsies. They occur most frequently in women with serous ovarian tumors, with borderline tumors (SBOT) having a higher i ... Full text Link to item Cite

Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.

Journal Article Clin Cancer Res · August 2000 Survival of African Americans with endometrial cancer is significantly worse than that of whites. Mutation of the PTEN tumor suppressor gene and microsatellite instability occur in some endometrial cancers, and they are associated with favorable prognostic ... Link to item Cite

InVEST: interactive and visual edge selection tool for constructing evolutionary trees.

Journal Article Pac Symp Biocomput · 2000 InVEST is an interactive and visual tool for constructing evolutionary trees from an ordered list of edges. In this paper it is shown that many methods for constructing evolutionary trees reduce to the edge selection problem. Furthermore, through a simulat ... Full text Link to item Cite

Prognosis of BRCA1 and 2-associated ovarian cancers

Journal Article CME Journal of Gynecologic Oncology · December 1, 1999 About 10% of epithelial ovarian cancers have a hereditary basis. Germline mutations in the BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes are thought to be responsible for most hereditary ovarian cancers. In contrast, about 90% of ovarian cance ... Cite

The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

Journal Article Clin Cancer Res · March 1999 The molecular biology underlying the metastatic process in ovarian carcinoma remains poorly understood. For other neoplasms, the induction of angiogenesis by malignant cells has been shown to play a pivotal role in the process of tumor proliferation and me ... Link to item Cite

Mutations in the PTEN tumor suppressor gene in cervical carcinomas

Journal Article International Journal of Gynecological Cancer · December 1, 1998 To elucidate further the molecular pathogenesis of cervical cancer we sought to determine whether mutations in the PTEN tumor suppressor gene are a feature of these cancers. Genomic DNA was extracted from 67 primary cervical cancers and 9 immortalized cerv ... Full text Cite

Second-look laparotomy in ovarian cancer

Journal Article Gynecologic Oncology · January 1, 1994 The role of the second-look laparotomy has become standard management in the patients with ovarian cancer without any objective evidence that it has a major impact on survival. In patients with early-stage disease, data on second-look surgery would suggest ... Full text Cite